Abstract
T cells, genetically modified by chimeric antigen receptors (CAR-T), are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing hematological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immunotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
U.S. Food and Drug Administration. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCom plianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UC M376521.pdf.
Abd El-Maqsoud, N.M., and Abd El-Rehim, D.M. (2014). Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer. Clin Breast Cancer 14, e1–e9
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M.C., Bosticardo, M., Evangelio, C., Assanelli, A., Casiraghi, M., Di Nunzio, S., Callegaro, L., Benati, C., Rizzardi, P., Pellin, D., Di Serio, C., Schmidt, M., Von Kalle, C., Gardner, J., Mehta, N., Neduva, V., Dow, D.J., Galy, A., Miniero, R., Finocchi, A., Metin, A., Banerjee, P.P., Orange, J.S., Galimberti, S., Valsecchi, M.G., Biffi, A., Montini, E., Villa, A., Ciceri, F., Roncarolo, M.G., and Naldini, L. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., Benedicenti, F., Vallanti, G., Biasco, L., Leo, S., Kabbara, N., Zanetti, G., Rizzo, W.B., Mehta, N.A., Cicalese, M.P., Casiraghi, M., Boelens, J.J., Del Carro, U., Dow, D.J., Schmidt, M., Assanelli, A., Neduva, V., Di Serio, C., Stupka, E., Gardner, J., von Kalle, C., Bordignon, C., Ciceri, F., Rovelli, A., Roncarolo, M.G., Aiuti, A., Sessa, M., and Naldini, L. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.
Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M., and Sadelain, M. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5, 177ra138.
Bryan, R.T., Shimwell, N.J., Wei, W., Devall, A.J., Pirrie, S.J., James, N.D., Zeegers, M.P., Cheng, K.K., Martin, A., and Ward, D.G. (2014). Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. Br J Cancer 110, 679–685.
Chinnasamy, D., Yu, Z., Kerkar, S.P., Zhang, L., Morgan, R.A., Restifo, N.P., and Rosenberg, S.A. (2012). Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18, 1672–1683.
Chmielewski, M., Kopecky, C., Hombach, A.A., and Abken, H. (2011). IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71, 5697–5706.
Couzin-Frankel, J. (2013). Cancer immunotherapy. Science 342, 1432–1433.
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., and Fu, Y.X. (2014). Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124, 687–695.
Driemel, C., Kremling, H., Schumacher, S., Will, D., Wolters, J., Lindenlauf, N., Mack, B., Baldus, S.A., Hoya, V., Pietsch, J.M., Panagiotidou, P., Raba, K., Vay, C., Vallbohmer, D., Harreus, U., Knoefel, W.T., Stoecklein, N.H., and Gires, O. (2014). Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene 33, 4904–4915.
Failli, A., Legitimo, A., Migheli, F., Coppede, F., Mathers, J.C., Spisni, R., Miccoli, P., Migliore, L., and Consolini, R. (2013). Efficacy and feasibility of the epithelial cell adhesion molecule (EpCAM) immunomagnetic cell sorter for studies of DNA methylation in colorectal cancer. Int J Mol Sci 15, 44–57.
Fong, D., Moser, P., Kasal, A., Seeber, A., Gastl, G., Martowicz, A., Wurm, M., Mian, C., Obrist, P., Mazzoleni, G., and Spizzo, G. (2014). Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology 64, 683–692.
Gee, A.P. (2015). Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther 22, 67–71.
Gilham, D.E., Debets, R., Pule, M., Hawkins, R.E., and Abken, H. (2012). CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18, 377–384.
Gross, G., Waks, T., and Eshhar, Z. (1989). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86, 10024–10028.
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L., and June, C.H. (2013). Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509–1518.
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A., and Cavazzana-Calvo, M. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419.
Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z., Burns, W.R., Huang, J., Klebanoff, C.A., Johnson, L.A., Kerkar, S.P., Yang, S., Muranski, P., Palmer, D.C., Scott, C.D., Morgan, R.A., Robbins, P.F., Rosenberg, S.A., and Restifo, N.P. (2010). Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808–814.
IKalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., and June, C.H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3, 95ra73.
Li, Y., Yin, J., Li, T., Huang, S., Yan H., Leavenworth, J.M., and Wang, X. (2015). NK cell-based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci 58, 1233–1245.
Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.-A.N., Lanier, B.J., Morgan, R.A., and Rosenberg, S.A. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102.
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., and Kurosawa, Y. (1987). Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149, 960–968.
Lee, J.C., Hayman, E., Pegram, H.J., Santos, E., Heller, G., Sadelain, M., and Brentjens, R. (2011). In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res 71, 2871–2881.
Moon, E.K., Carpenito, C., Sun, J., Wang, L.C., Kapoor, V., Predina, J.D., Powell, D.J., Riley, J., June, C.H., and Albelda, S.M. (2011). Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17, 4719–4730.
Ni, J., Cozzi, P., Hao, J., Beretov, J., Chang, L., Duan, W., Shigdar, S., Delprado, W., Graham, P., Bucci, J., Kearsley, J., and Li, Y. (2013). Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 45, 2736–2748.
Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., and Brentjens, R.J. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141.
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W.W., Lizee, G., Radvanyi, L., and Hwu, P. (2012). PD-1 Blockade enhances T-cell migration to tumors by elevating IFN-–inducible chemokines. Cance Res 72, 5209–5218.
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725–733.
Riddell, S.R., Sommermeyer, D., Berger, C., Liu, L.S., Balakrishnan, A., Salter, A., Hudecek, M., Maloney, D.G., and Turtle, C.J. (2014). Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20, 141–144.
Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.E. (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8, 299–308.
Tas, F., Karabulut, S., Serilmez, M., Ciftci, R., and Duranyildiz, D. (2013). Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumour Biol 35, 3095–3102.
Tsuji, T., Yasukawa, M., Matsuzaki, J., Ohkuri, T., Chamoto, K., Wakita, D., Azuma, T., Niiya, H., Miyoshi, H., Kuzushima, K., Oka, Y., Sugiyama, H., Ikeda, H., and Nishimura, T. (2005). Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106, 470–476.
Verma, I.M., and Somia, N. (1997). Gene therapy—promises, problems and prospects. Nature 389, 239–242.
Wang, W., and Wang, Y. (2012). Equipping CAR-modified T cells with a brake to prevent chronic adverse effects. Curr Gene Ther 12, 493–495.
Yang, Y., Fei, F., Song, Y., Li, X., Zhang, Z., Fei, Z., Su, H., and Wan, S. (2014). Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese. Cancer Sci 105, 89–96.
Yao, X., Ahmadzadeh, M., Lu, Y.C., Liewehr, D.J., Dudley, M.E., Liu, F., Schrump, D.S., Steinberg, S.M., Rosenberg, S.A., and Robbins, P.F. (2012). Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119, 5688–5696.
Yoshida, G.J., and Saya, H. (2014). EpCAM expression in the prostate cancer makes the difference in the response to growth factors. Biochem Biophys Res Commun 443, 239–245.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Wang, W., Qin, DY., Zhang, BL. et al. Establishing guidelines for CAR-T cells: challenges and considerations. Sci. China Life Sci. 59, 333–339 (2016). https://doi.org/10.1007/s11427-016-5026-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-5026-5